FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897541360> ?p ?o ?g. }

• W2897541360 endingPage "e133" @default.
• W2897541360 startingPage "e133" @default.
• W2897541360 abstract "Most published prostate SBRT studies treated low to intermediate-risk prostate cancer (CaP) with uniform doses of 35-40 Gy/ 5 fx. Previous attempts at uniform dose escalation to 50 Gy caused high rates of GI toxicity. We hypothesized heterogeneous dose escalation to 50 Gy to regions of the prostate not adjacent to the urethra, rectum and bladder is safe and efficacious. We report outcomes of an institutional phase II protocol. Thirty-five patients were enrolled on an institutional review board approved phase II study. Treatment involved LINAC based VMAT or IMRT with a rectal balloon. The contoured prostate was expanded by 3 mm (0 mm posteriorly). A prescription target of 50 Gy/ 5 fx was delivered to >50% of the portion of PTV >3 mm from sensitive structures (urethra, rectum, bladder), while the seminal vesicles and PTV <3mm from sensitive structures were treated to 36.25 Gy/ 5 fx. Study patients completed the EPIC-26 questionnaire at baseline and 1.5, 4, 8 and 12 months post SBRT. Clinically significant changes in quality of life (QOL) over time were determined using a minimally clinically important difference (MCID), defined as a change of >1/2 the standard deviation of the baseline QOL value. One patient had low, 12 intermediate (4 with multiple risk factors), and 16 high-risk CaP. Median and mean iPSAs were 9.0 and 16.6 ng/ml. Androgen deprivation therapy (median 6 months) was given to 17 patients (59%). Median age was 70 yrs. At median follow-up of 46 months, treatment was well-tolerated. Urinary irritation/obstructive and urinary bother scores declined by MCID threshold from baseline assessment to the first visit at six weeks post SBRT, but subsequently recovered by 4 months. No differences were observed for urinary incontinence, bowel domain, bloody stools, or sexual domain. One patient developed acute grade 2 GU toxicity and 2 patients developed acute grade 2 or higher GI toxicity. One patient developed late grade 2 GU toxicity and 4 patients developed late grade 2 or higher GI toxicity. This includes one patient with a very large prostate (270 cc) and implanted radiofrequency transponders who developed prostatic infection 3 weeks post SBRT, requiring surgical debridement resulting in acute and late grade 4 GI toxicities. Freedom from biochemical failure (nadir +2) at 3 years was 88.9%. Heterogeneous dose-escalated prostate SBRT was well-tolerated in patients with predominantly intermediate and high-risk CaP, with the exception of a single high grade toxicity of likely of infectious etiology. Urinary irritation/obstructive scores and urinary bother scores declined from baseline to six weeks post SBRT, but recovered by fourth months. There was no change in bloody stools or bowel domain scores with SBRT. Further investigation and follow-up is needed to establish the role of heterogeneous dose-escalated SBRT in CaP." @default.
• W2897541360 created "2018-10-26" @default.
• W2897541360 creator A5001069772 @default.
• W2897541360 creator A5013908031 @default.
• W2897541360 creator A5021058733 @default.
• W2897541360 creator A5024003297 @default.
• W2897541360 creator A5036420445 @default.
• W2897541360 creator A5036552905 @default.
• W2897541360 creator A5037174103 @default.
• W2897541360 creator A5045294159 @default.
• W2897541360 creator A5048152426 @default.
• W2897541360 creator A5073148665 @default.
• W2897541360 creator A5078447958 @default.
• W2897541360 date "2018-11-01" @default.
• W2897541360 modified "2023-10-06" @default.
• W2897541360 title "Heterogeneous Dose-Escalated Prostate Stereotactic Body Radiation Therapy for All Risk Prostate Cancer: Quality of Life and Clinical Outcomes of an Institutional Phase 2 Study" @default.
• W2897541360 doi "https://doi.org/10.1016/j.ijrobp.2018.07.253" @default.
• W2897541360 hasPublicationYear "2018" @default.
• W2897541360 type Work @default.
• W2897541360 sameAs 2897541360 @default.
• W2897541360 citedByCount "0" @default.
• W2897541360 crossrefType "journal-article" @default.
• W2897541360 hasAuthorship W2897541360A5001069772 @default.
• W2897541360 hasAuthorship W2897541360A5013908031 @default.
• W2897541360 hasAuthorship W2897541360A5021058733 @default.
• W2897541360 hasAuthorship W2897541360A5024003297 @default.
• W2897541360 hasAuthorship W2897541360A5036420445 @default.
• W2897541360 hasAuthorship W2897541360A5036552905 @default.
• W2897541360 hasAuthorship W2897541360A5037174103 @default.
• W2897541360 hasAuthorship W2897541360A5045294159 @default.
• W2897541360 hasAuthorship W2897541360A5048152426 @default.
• W2897541360 hasAuthorship W2897541360A5073148665 @default.
• W2897541360 hasAuthorship W2897541360A5078447958 @default.
• W2897541360 hasBestOaLocation W28975413601 @default.
• W2897541360 hasConcept C121608353 @default.
• W2897541360 hasConcept C126322002 @default.
• W2897541360 hasConcept C126838900 @default.
• W2897541360 hasConcept C126894567 @default.
• W2897541360 hasConcept C141071460 @default.
• W2897541360 hasConcept C159110408 @default.
• W2897541360 hasConcept C2776235491 @default.
• W2897541360 hasConcept C2777899217 @default.
• W2897541360 hasConcept C2779951463 @default.
• W2897541360 hasConcept C2780192828 @default.
• W2897541360 hasConcept C2781074409 @default.
• W2897541360 hasConcept C2989005 @default.
• W2897541360 hasConcept C509974204 @default.
• W2897541360 hasConcept C71924100 @default.
• W2897541360 hasConceptScore W2897541360C121608353 @default.
• W2897541360 hasConceptScore W2897541360C126322002 @default.
• W2897541360 hasConceptScore W2897541360C126838900 @default.
• W2897541360 hasConceptScore W2897541360C126894567 @default.
• W2897541360 hasConceptScore W2897541360C141071460 @default.
• W2897541360 hasConceptScore W2897541360C159110408 @default.
• W2897541360 hasConceptScore W2897541360C2776235491 @default.
• W2897541360 hasConceptScore W2897541360C2777899217 @default.
• W2897541360 hasConceptScore W2897541360C2779951463 @default.
• W2897541360 hasConceptScore W2897541360C2780192828 @default.
• W2897541360 hasConceptScore W2897541360C2781074409 @default.
• W2897541360 hasConceptScore W2897541360C2989005 @default.
• W2897541360 hasConceptScore W2897541360C509974204 @default.
• W2897541360 hasConceptScore W2897541360C71924100 @default.
• W2897541360 hasIssue "3" @default.
• W2897541360 hasLocation W28975413601 @default.
• W2897541360 hasOpenAccess W2897541360 @default.
• W2897541360 hasPrimaryLocation W28975413601 @default.
• W2897541360 hasRelatedWork W1544952821 @default.
• W2897541360 hasRelatedWork W1966419155 @default.
• W2897541360 hasRelatedWork W1982508997 @default.
• W2897541360 hasRelatedWork W2033896644 @default.
• W2897541360 hasRelatedWork W2085529113 @default.
• W2897541360 hasRelatedWork W2127440557 @default.
• W2897541360 hasRelatedWork W2969214722 @default.
• W2897541360 hasRelatedWork W4286561766 @default.
• W2897541360 hasRelatedWork W4308148977 @default.
• W2897541360 hasRelatedWork W83392053 @default.
• W2897541360 hasVolume "102" @default.
• W2897541360 isParatext "false" @default.
• W2897541360 isRetracted "false" @default.
• W2897541360 magId "2897541360" @default.
• W2897541360 workType "article" @default.